Pediatric MATCH Study Finds More Targetable Genetic Changes than Expected

An early report from the NCI–COG Pediatric MATCH trial shows that 24% of young patients with advanced cancer who had their tumors tested for genetic changes were eligible to receive one of the targeted therapies being tested.

Powered by WPeMatico